PerkinElmer Stock Price, News & Analysis (NYSE:PKI)

$76.18 +0.31 (+0.41 %)
(As of 02/22/2018 02:26 AM ET)
Previous Close$76.18
Today's Range$75.73 - $77.74
52-Week Range$53.97 - $84.49
Volume564,821 shs
Average Volume743,852 shs
Market Capitalization$8.36 billion
P/E Ratio54.03
Dividend Yield0.37%
Beta0.76

About PerkinElmer (NYSE:PKI)

PerkinElmer logoPerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
SectorHealthcare
SymbolNYSE:PKI
CUSIP71404610
Phone+1-781-6635776

Debt

Debt-to-Equity Ratio0.72%
Current Ratio1.27%
Quick Ratio0.90%

Price-To-Earnings

Trailing P/E Ratio54.0283687943262
Forward P/E Ratio21.64
P/E Growth1.76

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales3.72
Cash Flow$3.91 per share
Price / Cash19.47
Book Value$22.71 per share
Price / Book3.35

Profitability

Trailing EPS$1.41
Net Income$292.63 million
Net Margins12.97%
Return on Equity13.30%
Return on Assets6.51%

Miscellaneous

Employees8,000
Outstanding Shares110,220,000

PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Friday, January 26th. Investors of record on Friday, April 13th will be paid a dividend of $0.07 per share on Thursday, May 10th. This represents a $0.28 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date is Thursday, April 12th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings results on Thursday, January, 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.94 by $0.03. The medical research company had revenue of $641.63 million for the quarter, compared to the consensus estimate of $619.14 million. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. PerkinElmer's revenue was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.83 earnings per share. View PerkinElmer's Earnings History.

When will PerkinElmer make its next earnings announcement?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its FY18 earnings guidance on Thursday, January, 25th. The company provided earnings per share (EPS) guidance of approx $3.50 for the period, compared to the Thomson Reuters consensus estimate of $3.47.

Where is PerkinElmer's stock going? Where will PerkinElmer's stock price be in 2018?

13 brokerages have issued twelve-month price objectives for PerkinElmer's shares. Their forecasts range from $65.00 to $88.00. On average, they anticipate PerkinElmer's stock price to reach $76.08 in the next year. View Analyst Ratings for PerkinElmer.

What are Wall Street analysts saying about PerkinElmer stock?

Here are some recent quotes from research analysts about PerkinElmer stock:

  • 1. According to Zacks Investment Research, "PerkinElmer’s share price movement in the last year has been unsatisfactory. However, the company is well poised on solid organic revenue growth. Furthermore, a positive guidance instills our confidence in the stock. PerkinElmer’s strong global foothold is noteworthy, courtesy of its acquisition of Germany-based EUROIMMUN and India-based Tulip Diagnostics. The acquisition of EUROIMMUN should expand PerkinElmer’s reach into autoimmune and allergy diagnostic markets. Management expects the addition to drive R&D expense margin. With an enhanced focus on product innovation, PerkinElmer has considerable potential upside. On the flipside, despite having a solid portfolio, unfavorable foreign exchange is a primary concern. PerkinElmer continues to acquire a large number of companies. While this improves revenue opportunities, it adds to integration risks. Also, high debt levels may hinder the company’s expansion plans." (1/8/2018)
  • 2. Cantor Fitzgerald analysts commented, "Newborn screening in China continues to drive strong diagnostic growth, despite a slight decline in the Haoyuan nucleic acid testing. Diagnostic revenue in China was up more than 20% y/y in 1Q17. Despite a slight moderation in birth rates, uptake of the automated Genetic Screening Processor (GSP) has driven menu expansion. The company reports that 20-25% of the market is now screening for ~20 disorders, while the remaining 80% is screening for 2-4 disorders. India, the largest newborn screening opportunity with an estimated 26M annual births, continues to be relatively unpenetrated, but we do not anticipate a steep adoption ramp as the company experienced in China. Increase in reported revenue guidance leaves organic growth unchanged. The company raised its 2017 revenue guidance to $2.200-2.220B from $2.19-2.20B, implying 4-5% y/y reported revenue growth, compared with our prior estimate of $2.199B. Notably, the 4% organic revenue growth rate is unchanged, and the company expects a slightly lower FX headwind for 2017." (5/5/2017)

Who are some of PerkinElmer's key competitors?

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:

  • Robert F. Friel, Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Frank Anders Wilson CPA, Chief Financial Officer, Senior Vice President (Age 58)
  • Deborah Butters, Chief Human Resource Officer, Senior Vice President (Age 47)
  • James L. Corbett, Executive Vice President and President - Discovery & Analytical Solutions (Age 54)
  • Joel S. Goldberg, Senior Vice President - Administration, General Counsel, Secretary (Age 48)
  • Prahlad R. Singh, Senior Vice President and President - Diagnostics (Age 52)
  • Daniel R. Tereau, Senior Vice President, Strategy and Business Development (Age 50)
  • Andrew Okun, Chief Accounting Officer, Vice President (Age 47)
  • Alexis P. Michas, Lead Independent Director (Age 59)
  • Pascale Witz, Director

Who owns PerkinElmer stock?

PerkinElmer's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.68%), King Luther Capital Management Corp (2.31%), Geode Capital Management LLC (1.15%), Goldman Sachs Group Inc. (1.15%), Bank of New York Mellon Corp (0.91%) and Westwood Holdings Group Inc. (0.76%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Frank Anders Wilson, James Corbett, Joel S Goldberg, Kenton J Sicchitano, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer.

Who sold PerkinElmer stock? Who is selling PerkinElmer stock?

PerkinElmer's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Millennium Management LLC, Citadel Advisors LLC, Assenagon Asset Management S.A., Acadian Asset Management LLC, Goldman Sachs Group Inc., Schroder Investment Management Group and Edinburgh Partners Ltd. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Frank Anders Wilson, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Insider Buying and Selling for PerkinElmer.

Who bought PerkinElmer stock? Who is buying PerkinElmer stock?

PerkinElmer's stock was acquired by a variety of institutional investors in the last quarter, including American Century Companies Inc., BlackRock Inc., Sensato Investors LLC, AXA, Amundi Pioneer Asset Management Inc., Daiwa Securities Group Inc., Icon Advisers Inc. Co. and Allianz Asset Management GmbH. View Insider Buying and Selling for PerkinElmer.

How do I buy PerkinElmer stock?

Shares of PerkinElmer can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PerkinElmer stock can currently be purchased for approximately $76.18.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $8.36 billion and generates $2.26 billion in revenue each year. The medical research company earns $292.63 million in net income (profit) each year or $1.41 on an earnings per share basis. PerkinElmer employs 8,000 workers across the globe.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 Winter St, WALTHAM, MA 02451-1457, United States. The medical research company can be reached via phone at +1-781-6635776 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (PKI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  621
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PerkinElmer (NYSE:PKI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.312.292.202.15
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $76.08$72.58$68.23$66.91
Price Target Upside: 8.06% downside4.70% downside3.56% downside1.69% upside

PerkinElmer (NYSE:PKI) Consensus Price Target History

Price Target History for PerkinElmer (NYSE:PKI)

PerkinElmer (NYSE:PKI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2018BarclaysBoost Price TargetUnderweight -> Underweight$69.00 -> $73.00LowView Rating Details
1/26/2018CowenReiterated RatingHold$84.00LowView Rating Details
1/26/2018Robert W. BairdReiterated RatingBuy$88.00MediumView Rating Details
1/3/2018Evercore ISIInitiated CoverageIn-Line$77.00LowView Rating Details
12/19/2017Bank of AmericaUpgradeUnderperform -> Neutral$78.00LowView Rating Details
11/3/2017Morgan StanleyBoost Price TargetOverweight$77.00 -> $78.00N/AView Rating Details
10/20/2017Jefferies GroupReiterated RatingHold$70.00N/AView Rating Details
9/26/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$67.00LowView Rating Details
9/26/2017CitigroupReiterated RatingBuy$74.00 -> $80.00LowView Rating Details
8/4/2017Piper Jaffray CompaniesReiterated RatingBuy$81.00MediumView Rating Details
7/16/2017Cantor FitzgeraldReiterated RatingHoldLowView Rating Details
7/13/2017Wells Fargo & CoInitiated CoverageMarket Perform -> Market Perform$72.00LowView Rating Details
3/27/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
2/5/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
1/18/2017Deutsche BankReiterated RatingHold$55.00N/AView Rating Details
8/5/2016JPMorgan Chase & Co.Boost Price TargetNeutral$52.00 -> $55.00N/AView Rating Details
8/5/2016MizuhoDowngradeBuy -> Neutral$56.00N/AView Rating Details
5/6/2016Stifel NicolausBoost Price TargetBuy$51.00 -> $59.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

PerkinElmer (NYSE:PKI) Earnings History and Estimates Chart

Earnings by Quarter for PerkinElmer (NYSE:PKI)

PerkinElmer (NYSE PKI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.62N/AView Earnings Details
1/25/2018Q4 2017$0.94$0.97$619.14 million$641.63 millionViewN/AView Earnings Details
11/2/2017Q3 2017$0.72$0.73$552.38 million$554.28 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.67$0.67$554.14 million$547.00 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.54$0.55$506.81 million$514.12 millionViewListenView Earnings Details
2/2/2017Q4 2016$0.86$0.83$613.15 million$566.77 millionViewN/AView Earnings Details
11/7/2016Q3$0.66$0.68$572.03 million$548.00 millionViewListenView Earnings Details
8/4/2016Q2 2016$0.66$0.67$573.31 million$572.67 millionViewN/AView Earnings Details
5/5/2016Q116$0.51$0.56$532.55 million$538.70 millionViewN/AView Earnings Details
2/4/2016Q4 2015$0.87$0.86$616.70 million$608.12 millionViewN/AView Earnings Details
11/5/2015Q315$0.60$0.60$554.88 million$563.00 millionViewN/AView Earnings Details
7/30/2015Q2$0.59$0.60$555.66 million$564.00 millionViewListenView Earnings Details
4/30/2015Q115$0.46$0.50$537.27 million$526.90 millionViewN/AView Earnings Details
1/29/2015Q414$0.78$0.85$602.35 million$608.60 millionViewN/AView Earnings Details
10/30/2014Q3$0.57$0.67$550.40 million$542.05 millionViewListenView Earnings Details
8/7/2014Q2$0.59$0.59$572.26 million$556.20 millionViewListenView Earnings Details
4/24/2014Q114$0.44$0.46$531.31 million$531.90 millionViewListenView Earnings Details
1/30/2014Q413$0.70$0.73$588.95 million$594.00 millionViewListenView Earnings Details
10/30/2013Q313$0.48$0.49$523.84 million$524.30 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.48$0.51$532.95 million$543.30 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.48$0.36$532.25 million$505.38 millionViewListenView Earnings Details
1/31/2013Q4 2012$0.65$0.65$577.94 million$577.00 millionViewListenView Earnings Details
10/25/2012$0.44$0.45ViewN/AView Earnings Details
8/2/2012$0.47$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.43ViewN/AView Earnings Details
2/2/2012$0.51$0.62ViewN/AView Earnings Details
11/3/2011$0.39$0.41ViewN/AView Earnings Details
8/4/2011$0.40$0.42ViewN/AView Earnings Details
5/5/2011$0.31$0.34ViewN/AView Earnings Details
2/3/2011$0.41$0.44ViewN/AView Earnings Details
11/4/2010Q3 2010$0.29$0.31ViewN/AView Earnings Details
8/5/2010Q2 2010$0.33$0.38ViewN/AView Earnings Details
5/6/2010Q1 2010$0.29$0.31ViewN/AView Earnings Details
2/4/2010Q4 2009$0.41$0.43ViewN/AView Earnings Details
10/29/2009Q3 2009$0.27$0.30ViewN/AView Earnings Details
7/30/2009Q2 2009$0.26$0.28ViewN/AView Earnings Details
4/30/2009Q1 2009$0.20$0.26ViewN/AView Earnings Details
1/29/2009Q4 2008$0.42$0.46ViewN/AView Earnings Details
10/23/2008Q3 2008$0.36$0.37ViewN/AView Earnings Details
7/24/2008Q2 2008$0.34$0.35ViewN/AView Earnings Details
4/24/2008Q1 2008$0.25$0.28ViewN/AView Earnings Details
1/24/2008Q4 2007$0.42$0.45ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

PerkinElmer (NYSE:PKI) Earnings Estimates

2018 EPS Consensus Estimate: $3.69
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.80$0.80$0.80
Q2 20181$0.84$0.84$0.84
Q3 20181$0.90$0.90$0.90
Q4 20181$1.15$1.15$1.15
(Earnings estimates data provided by Zacks Investment Research)

Dividends

PerkinElmer (NYSE:PKI) Dividend Information

Next Dividend:5/10/2018
Annual Dividend:$0.28
Dividend Yield:0.37%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:19.86% (Trailing 12 Months of Earnings)
7.95% (Based on This Year's Estimates)
7.05% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for PerkinElmer (NYSE:PKI)

PerkinElmer (NYSE:PKI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/26/2018quarterly$0.070.000845410628019324%4/12/20184/13/20185/10/2018
10/27/2017quarterly$0.070.39%1/18/20181/19/20182/9/2018
7/24/2017quarterly$0.070.41%10/19/201710/20/201711/10/2017
4/28/2017quarterly$0.070.47%7/19/20177/21/20178/10/2017
1/27/2017quarterly$0.070.54%4/11/20174/14/20175/10/2017
10/26/2016quarterly$0.070.55%1/18/20171/20/20172/10/2017
7/27/2016quarterly$0.070.5%10/12/201610/14/201611/10/2016
4/25/2016quarterly$0.070.55%7/13/20167/15/20168/10/2016
1/28/2016quarterly$0.070.58%4/13/20164/15/20165/10/2016
10/29/2015quarterly$0.070.54%1/13/20161/15/20162/10/2016
7/23/2015quarterly$0.070.55%10/14/201510/16/201511/10/2015
4/27/2015quarterly$0.070.54%7/15/20157/17/20158/10/2015
1/23/2015quarterly$0.070.63%4/15/20154/17/20155/11/2015
10/23/2014quarterly$0.070.67%1/14/20151/16/20152/6/2015
7/24/2014quarterly$0.070.59%10/15/201410/17/201411/7/2014
4/22/2014quarterly$0.070.63%7/16/20147/18/20148/8/2014
1/24/2014quarterly$0.070.68%4/15/20144/18/20145/9/2014
10/24/2013quarterly$0.070.73%1/15/20141/17/20142/7/2014
7/26/2013quarterly$0.070.82%10/16/201310/18/201311/8/2013
6/13/2013quarterly$0.070.85%7/17/20137/19/20138/9/2013
1/25/2013quarterly$0.070.79%4/17/20134/19/20135/10/2013
(Data available from 1/1/2013 forward)

Insider Trades

PerkinElmer (NYSE PKI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 90.06%
Insider Trades by Quarter for PerkinElmer (NYSE:PKI)
Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

PerkinElmer (NYSE PKI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018Andrew OkunInsiderSell2,324$75.44$175,322.568,876View SEC Filing  
2/5/2018Andrew OkunInsiderSell2,273$77.86$176,975.78View SEC Filing  
12/15/2017Andrew OkunInsiderSell12,680$72.00$912,960.0025,121View SEC Filing  
12/7/2017Frank Anders WilsonInsiderSell37,535$70.14$2,632,704.90View SEC Filing  
11/30/2017Alexis P MichasDirectorSell5,000$73.18$365,900.00View SEC Filing  
11/13/2017Peter BarrettDirectorSell7,071$71.07$502,535.9726,271View SEC Filing  
11/7/2017Nicholas A LopardoDirectorSell24,050$70.72$1,700,816.00View SEC Filing  
6/19/2017Andrew OkunInsiderSell4,358$65.00$283,270.0016,799View SEC Filing  
6/1/2017Peter BarrettDirectorSell10,000$63.22$632,200.0029,200View SEC Filing  
5/15/2017Patrick J SullivanDirectorSell6,628$62.59$414,846.5242,951View SEC Filing  
5/4/2017Robert F FrielInsiderSell25,100$60.00$1,506,000.00597,071View SEC Filing  
4/27/2017Robert F FrielInsiderSell124,837$60.11$7,503,952.07696,810View SEC Filing  
3/20/2017Andrew OkunInsiderSell3,000$57.27$171,810.0012,441View SEC Filing  
3/13/2017Joel S GoldbergInsiderSell30,710$55.45$1,702,869.5091,768View SEC Filing  
2/21/2017Alexis P. MichasDirectorSell8,308$55.60$461,924.80View SEC Filing  
2/15/2017Prahlad R SinghInsiderSell9,576$55.00$526,680.0016,319View SEC Filing  
2/9/2017Daniel R TereauInsiderSell5,001$53.16$265,853.1612,147View SEC Filing  
2/9/2017Vicki L SatoDirectorSell8,308$54.01$448,715.0838,278View SEC Filing  
2/6/2017Daniel R TereauInsiderSell4,069$52.01$211,628.699,465View SEC Filing  
12/1/2016Alexis P. MichasDirectorSell15,000$51.00$765,000.00View SEC Filing  
9/22/2016Joel S GoldbergInsiderSell38,095$55.00$2,095,225.0096,299View SEC Filing  
9/12/2016Daniel R TereauInsiderSell18,866$52.00$981,032.0021,241View SEC Filing  
8/24/2016Kenton J SicchitanoDirectorSell15,189$54.87$833,420.4343,160View SEC Filing  
8/17/2016Patrick J SullivanDirectorSell8,308$54.74$454,779.9241,829View SEC Filing  
6/2/2016Alexis P MichasDirectorSell1,953$54.85$107,122.0568,290View SEC Filing  
5/24/2016Robert F FrielCEOSell128,300$55.01$7,057,783.00690,831View SEC Filing  
5/16/2016Robert F FrielCEOSell109,000$55.01$5,996,090.00569,953View SEC Filing  
5/11/2016Robert F FrielCEOSell10,685$55.01$587,781.85573,216View SEC Filing  
5/10/2016Vicki L SatoDirectorSell12,586$54.51$686,062.8636,960View SEC Filing  
5/6/2016Robert F FrielCEOSell4,116$55.00$226,380.00566,647View SEC Filing  
4/18/2016Daniel R TereauInsiderSell2,158$50.79$109,604.828,602View SEC Filing  
3/21/2016James CorbettInsiderSell1,723$48.74$83,979.0228,881View SEC Filing  
2/24/2016Alexis P. MichasDirectorSell10,000$47.56$475,600.00View SEC Filing  
12/3/2015Kenton J SicchitanoDirectorSell10,216$51.05$521,526.8031,658View SEC Filing  
11/3/2015Frank Anders WilsoninsiderSell16,380$52.69$863,062.2055,859View SEC Filing  
10/23/2015Andrew OkunInsiderSell2,000$50.00$100,000.0011,278View SEC Filing  
9/14/2015James CorbettInsiderSell3,000$47.59$142,770.0021,664View SEC Filing  
9/3/2015Kenton J. SicchitanoDirectorSell12,586$47.88$602,617.6841,874View SEC Filing  
6/5/2015Alexis P MichasDirectorSell20,000$52.25$1,045,000.00View SEC Filing  
6/3/2015Frank Anders WilsonInsiderSell16,380$52.60$861,588.00View SEC Filing  
3/27/2015Joel S GoldbergInsiderSell10,646$51.00$542,946.00View SEC Filing  
3/23/2015Andrew OkunInsiderSell2,000$50.09$100,180.00View SEC Filing  
3/20/2015James CorbettInsiderSell5,157$50.23$259,036.11View SEC Filing  
3/18/2015Joel S GoldbergInsiderSell9,000$49.00$441,000.00View SEC Filing  
3/6/2015Patrick J SullivanDirectorSell12,586$46.90$590,283.40View SEC Filing  
3/5/2015Alexis P MichasDirectorSell8,892$47.00$417,924.00View SEC Filing  
3/5/2015Joel S GoldbergInsiderSell9,000$47.00$423,000.00View SEC Filing  
2/10/2015Vicki L SatoDirectorSell24,000$45.55$1,093,200.00View SEC Filing  
2/9/2015Andrew OkunInsiderSell6,262$45.82$286,924.84View SEC Filing  
2/3/2015Nicholas A LopardoDirectorSell8,892$46.30$411,699.60View SEC Filing  
2/3/2015Robert F FrielCEOSell60,709$46.26$2,808,398.34View SEC Filing  
2/2/2015Robert F FrielCEOSell319,065$46.02$14,683,371.30View SEC Filing  
11/14/2014James C MullenDirectorSell8,892$43.73$388,847.16View SEC Filing  
11/13/2014Patrick J SullivanDirectorSell8,892$43.46$386,446.32View SEC Filing  
9/4/2014Kenton J SicchitanoDirectorSell8,892$44.98$399,962.16View SEC Filing  
7/2/2014Daniel R MarshakSVPSell12,000$48.00$576,000.00View SEC Filing  
6/26/2014Daniel R MarshakSVPSell10,000$46.60$466,000.00View SEC Filing  
6/19/2014James CorbettInsiderSell57,126$46.69$2,667,212.94View SEC Filing  
6/9/2014Maurice H TenneyInsiderSell5,504$47.26$260,119.04View SEC Filing  
6/9/2014Robert F FrielCEOSell124,858$46.70$5,830,868.60View SEC Filing  
6/5/2014Alexis P MichasDirectorSell9,146$46.30$423,459.80View SEC Filing  
6/2/2014Alexis P MichasDirectorSell5,854$45.00$263,430.00View SEC Filing  
6/2/2014Joel S GoldbergInsiderSell17,000$45.11$766,870.00View SEC Filing  
5/12/2014Alexis MichasDirectorSell5,000$44.40$222,000.0096,321View SEC Filing  
4/29/2014Nicholas LopardoDirectorSell12,951$41.98$543,682.9878,622View SEC Filing  
4/7/2014James CorbettInsiderSell22,027$45.11$993,637.9721,858View SEC Filing  
3/12/2014Daniel MarshakSVPSell19,292$45.29$873,734.6845,445View SEC Filing  
3/11/2014John LetcherSVPSell41,000$45.40$1,861,400.0034,514View SEC Filing  
3/7/2014Andrew OkunCAOSell9,398$46.35$435,597.3013,816View SEC Filing  
2/27/2014Alexis MichasDirectorSell5,000$45.25$226,250.0095,067View SEC Filing  
2/14/2014Vicki SatoDirectorSell21,843$43.97$960,436.7145,370View SEC Filing  
2/7/2014James MullenDirectorSell12,951$43.73$566,347.2343,178View SEC Filing  
12/13/2013Maurice TenneyInsiderSell25,000$38.91$972,750.0026,109View SEC Filing  
12/10/2013Daniel MarshakSVPSell12,183$39.59$482,324.9742,762View SEC Filing  
11/14/2013Robert FrielCEOSell112,461$37.14$4,176,801.54516,849View SEC Filing  
9/10/2013Robert F FrielCEOSell141,000$37.45$5,280,450.00View SEC Filing  
9/6/2013Andrew OkunCAOSell6,805$36.86$250,832.30View SEC Filing  
5/1/2013Alexis P MichasDirectorSell6,440$30.85$198,674.00View SEC Filing  
4/30/2013James C MullenDirectorSell6,440$30.31$195,196.40View SEC Filing  
4/11/2013Maurice H TenneyInsiderSell9,500$35.00$332,500.00View SEC Filing  
9/13/2012Robert F FrielCEOSell50,565$29.00$1,466,385.00View SEC Filing  
8/9/2012Kenton J SicchitanoDirectorSell9,454$27.93$264,050.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PerkinElmer (NYSE PKI) News Headlines

Source:
DateHeadline
5 Reasons to Invest in PerkinElmer (PKI) Stock Right Now5 Reasons to Invest in PerkinElmer (PKI) Stock Right Now
www.zacks.com - February 13 at 8:00 AM
Here's Why You Should Sweep Up Quest Diagnostics Right NowHere's Why You Should Sweep Up Quest Diagnostics Right Now
finance.yahoo.com - February 13 at 8:00 AM
Becton, Dickinson Gains on Strong Q1 Results & AcquisitionsBecton, Dickinson Gains on Strong Q1 Results & Acquisitions
finance.yahoo.com - February 13 at 8:00 AM
Luminex (LMNX) Beats on Q4 Earnings & Revenues, Issues ViewLuminex (LMNX) Beats on Q4 Earnings & Revenues, Issues View
finance.yahoo.com - February 13 at 8:00 AM
Amedisys (AMED) Strong on Home Health, Margin Decline a WoeAmedisys (AMED) Strong on Home Health, Margin Decline a Woe
finance.yahoo.com - February 12 at 3:33 PM
PerkinElmer, Inc. (PKI) Receives Consensus Recommendation of "Hold" from AnalystsPerkinElmer, Inc. (PKI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 10 at 9:10 AM
Insider Selling: PerkinElmer, Inc. (PKI) Insider Sells 2,324 Shares of StockInsider Selling: PerkinElmer, Inc. (PKI) Insider Sells 2,324 Shares of Stock
www.americanbankingnews.com - February 9 at 6:32 PM
QIAGEN Strong on Molecular Diagnostics, Competition RifeQIAGEN Strong on Molecular Diagnostics, Competition Rife
finance.yahoo.com - February 9 at 3:41 PM
PerkinElmer, Inc. (PKI) Expected to Announce Quarterly Sales of $615.81 MillionPerkinElmer, Inc. (PKI) Expected to Announce Quarterly Sales of $615.81 Million
www.americanbankingnews.com - February 9 at 1:48 AM
CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View UpbeatCVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat
finance.yahoo.com - February 8 at 3:32 PM
Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 ViewCardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View
finance.yahoo.com - February 8 at 3:32 PM
Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View UpHaemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up
finance.yahoo.com - February 8 at 7:40 AM
PerkinElmer, Inc. (PKI) Insider Sells $176,975.78 in StockPerkinElmer, Inc. (PKI) Insider Sells $176,975.78 in Stock
www.americanbankingnews.com - February 8 at 12:48 AM
LabCorp (LH) Q4 Earnings Beat Estimates, '18 View PromisingLabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising
finance.yahoo.com - February 6 at 3:32 PM
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
finance.yahoo.com - February 5 at 3:31 PM
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables UpPacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
www.msn.com - February 2 at 3:35 PM
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and RevenuesIDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
finance.yahoo.com - February 1 at 3:32 PM
Jefferies Group Brokers Reduce Earnings Estimates for PerkinElmer, Inc. (PKI)Jefferies Group Brokers Reduce Earnings Estimates for PerkinElmer, Inc. (PKI)
www.americanbankingnews.com - January 29 at 3:44 AM
Robert W. Baird Reaffirms "Buy" Rating for PerkinElmer (PKI)Robert W. Baird Reaffirms "Buy" Rating for PerkinElmer (PKI)
www.americanbankingnews.com - January 27 at 11:44 AM
Barclays Boosts PerkinElmer (PKI) Price Target to $73.00Barclays Boosts PerkinElmer (PKI) Price Target to $73.00
www.americanbankingnews.com - January 26 at 5:24 PM
PerkinElmers (PKI) Hold Rating Reaffirmed at CowenPerkinElmer's (PKI) Hold Rating Reaffirmed at Cowen
www.americanbankingnews.com - January 26 at 4:18 PM
PerkinElmer, Inc. Announces Quarterly Dividend of $0.07 (PKI)PerkinElmer, Inc. Announces Quarterly Dividend of $0.07 (PKI)
www.americanbankingnews.com - January 26 at 9:06 AM
PerkinElmer (PKI) Beats on Q4 Earnings, Issues 2018 GuidancePerkinElmer (PKI) Beats on Q4 Earnings, Issues 2018 Guidance
www.zacks.com - January 26 at 7:45 AM
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2017PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2017
finance.yahoo.com - January 26 at 7:45 AM
PerkinElmer reports 4Q lossPerkinElmer reports 4Q loss
finance.yahoo.com - January 26 at 7:45 AM
PerkinElmer profit, 2018 forecast top Wall Street estimatesPerkinElmer profit, 2018 forecast top Wall Street estimates
finance.yahoo.com - January 26 at 7:45 AM
PerkinElmer (PKI) Updates FY18 Earnings GuidancePerkinElmer (PKI) Updates FY18 Earnings Guidance
www.americanbankingnews.com - January 25 at 5:04 PM
Did PerkinElmer Inc’s (NYSE:PKI) Recent Earnings Growth Beat The Trend?Did PerkinElmer Inc’s (NYSE:PKI) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - January 25 at 7:46 AM
PerkinElmer (PKI) Scheduled to Post Earnings on WednesdayPerkinElmer (PKI) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - January 24 at 3:56 AM
Zacks: Brokerages Expect PerkinElmer, Inc. (PKI) Will Announce Quarterly Sales of $615.80 MillionZacks: Brokerages Expect PerkinElmer, Inc. (PKI) Will Announce Quarterly Sales of $615.80 Million
www.americanbankingnews.com - January 23 at 4:28 AM
PerkinElmer, Inc. (PKI) Expected to Announce Earnings of $0.94 Per SharePerkinElmer, Inc. (PKI) Expected to Announce Earnings of $0.94 Per Share
www.americanbankingnews.com - January 21 at 5:20 PM
PerkinElmer Hits 52-Week High: Whats Driving the Stock?PerkinElmer Hits 52-Week High: What's Driving the Stock?
www.nasdaq.com - January 19 at 5:01 PM
Key Factors to Influence PerkinElmer's (PKI) Q4 EarningsKey Factors to Influence PerkinElmer's (PKI) Q4 Earnings
finance.yahoo.com - January 19 at 11:48 AM
Key Factors to Influence PerkinElmers (PKI) Q4 EarningsKey Factors to Influence PerkinElmer's (PKI) Q4 Earnings
www.zacks.com - January 18 at 4:07 PM
Zacks Investment Research Upgrades PerkinElmer (PKI) to "Buy"Zacks Investment Research Upgrades PerkinElmer (PKI) to "Buy"
www.americanbankingnews.com - January 8 at 3:26 PM
$615.80 Million in Sales Expected for PerkinElmer, Inc. (PKI) This Quarter$615.80 Million in Sales Expected for PerkinElmer, Inc. (PKI) This Quarter
www.americanbankingnews.com - January 6 at 2:14 AM
PerkinElmer to Hold Earnings Call on Thursday, January 25, 2018PerkinElmer to Hold Earnings Call on Thursday, January 25, 2018
finance.yahoo.com - January 5 at 4:19 PM
$0.94 Earnings Per Share Expected for PerkinElmer, Inc. (PKI) This Quarter$0.94 Earnings Per Share Expected for PerkinElmer, Inc. (PKI) This Quarter
www.americanbankingnews.com - January 4 at 9:44 PM
PerkinElmer (PKI) Now Covered by Evercore ISIPerkinElmer (PKI) Now Covered by Evercore ISI
www.americanbankingnews.com - January 3 at 10:02 PM
Financial Comparison: PerkinElmer (PKI) vs. Accelerate Diagnostics (AXDX)Financial Comparison: PerkinElmer (PKI) vs. Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - December 31 at 11:14 PM
PerkinElmer to Present at J.P. Morgan 36th Annual Healthcare ConferencePerkinElmer to Present at J.P. Morgan 36th Annual Healthcare Conference
finance.yahoo.com - December 27 at 4:59 PM
ETFs with exposure to PerkinElmer, Inc. (United States) : December 25, 2017ETFs with exposure to PerkinElmer, Inc. (United States) : December 25, 2017
finance.yahoo.com - December 25 at 6:09 PM
PerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3B - NasdaqPerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3B - Nasdaq
www.nasdaq.com - December 23 at 12:31 AM
Bank of America Upgrades PerkinElmer (PKI) to NeutralBank of America Upgrades PerkinElmer (PKI) to Neutral
www.americanbankingnews.com - December 20 at 12:20 AM
PerkinElmer Completes Acquisition of EUROIMMUNPerkinElmer Completes Acquisition of EUROIMMUN
finance.yahoo.com - December 19 at 4:34 PM
$0.94 EPS Expected for PerkinElmer, Inc. (PKI) This Quarter$0.94 EPS Expected for PerkinElmer, Inc. (PKI) This Quarter
www.americanbankingnews.com - December 19 at 9:32 AM
PerkinElmer, Inc. (PKI) Insider Andrew Okun Sells 12,680 SharesPerkinElmer, Inc. (PKI) Insider Andrew Okun Sells 12,680 Shares
www.americanbankingnews.com - December 18 at 5:50 PM
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bullish Manner : PKI-US : December 18, 2017PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bullish Manner : PKI-US : December 18, 2017
finance.yahoo.com - December 18 at 10:45 AM
ETFs with exposure to PerkinElmer, Inc. (United States) : December 13, 2017ETFs with exposure to PerkinElmer, Inc. (United States) : December 13, 2017
finance.yahoo.com - December 13 at 4:46 PM
PerkinElmer, Inc. (United States) :PKI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 12, 2017PerkinElmer, Inc. (United States) :PKI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 12, 2017
finance.yahoo.com - December 12 at 10:47 AM

SEC Filings

PerkinElmer (NYSE:PKI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PerkinElmer (NYSE:PKI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PerkinElmer (NYSE PKI) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.